About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Gastroenterology Center
›
Top Articles
Gastroenterology Center
187
(top 1%)
papers
10.8K
(top 1%)
citations
29
(top 1%)
h
-index
101
(top 1%)
g
-index
190
all documents
11.5K
doc citations
1.6K
citing journals
172
times ranked
Top Articles
#
Title
Journal
Year
Citations
1
Preoperative assessment of liver function: a comparison of 99mTc-Mebrofenin scintigraphy with indocyanine green clearance test
Liver International
2004
7,546
2
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Liver Cancer
2021
307
3
Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function
Liver Cancer
2017
202
4
Usefulness of albumin–bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma
Journal of Gastroenterology and Hepatology (Australia)
2016
198
5
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications
Liver Cancer
2017
159
6
Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis
Liver Cancer
2019
159
7
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
Cancer Medicine
2019
131
8
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis
Digestive Diseases
2017
113
9
Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis
Cancer Medicine
2019
112
10
Muscle atrophy as pre-sarcopenia in Japanese patients with chronic liver disease: computed tomography is useful for evaluation
Journal of Gastroenterology
2015
90
11
Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients
Liver Cancer
2019
88
12
Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib
Hepatology Research
2017
82
13
Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis
Hepatology Research
2019
81
14
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma
Oncology
2019
66
15
Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib
Liver International
2020
51
16
Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan
Journal of Gastroenterology
2018
49
17
Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis
Liver International
2021
45
18
Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching
Hepatology Research
2020
44
19
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
Cancer Reports
2022
43
20
LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
Annals of Oncology
2022
43
21
Colonic Intussusception Caused by Anisakiasis: A Case Report and Review of the Literature
Internal Medicine
2013
42
22
Role of hepatic resection in patients with intermediate‐stage hepatocellular carcinoma: A multicenter study from Japan
Cancer Science
2017
40
23
Impact of albumin–bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time‐dependent receiver operating characteristic
Journal of Gastroenterology and Hepatology (Australia)
2019
40
24
Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma
Oncology
2019
39
25
Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade
Oncology
2016
36
26
EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis
Liver Cancer
2020
35
27
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study
Hepatology International
2022
35
28
Effect of direct oral anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection
Digestive Endoscopy
2017
34
29
Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma
Cancers
2020
34
30
Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study
Hepatology Research
2021
33
31
Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization
Oncology
2015
31
32
Prognosis and therapy for ruptured hepatocellular carcinoma: Problems with staging and treatment strategy
European Journal of Radiology
2015
31
33
ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Advantage of ALBI Grade for Universal Assessment of Hepatic Function
Liver Cancer
2017
30
34
Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
American Journal of Roentgenology
2018
30
35
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
Scientific Reports
2021
30
36
Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan
Liver Cancer
2019
28
37
Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting
Journal of Gastroenterology and Hepatology (Australia)
2021
28
38
Neutrophil–lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis
European Journal of Gastroenterology and Hepatology
2022
27
39
Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study
Journal of Gastroenterology and Hepatology (Australia)
2019
26
40
Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan
Journal of Gastroenterology
2018
25
41
Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma
Japanese Journal of Clinical Oncology
2019
25
42
The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study
Hepatology International
2020
25
43
Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria
Journal of Gastroenterology
2021
25
44
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib
ESMO Open
2021
25
45
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis
Hepatology Research
2022
25
46
Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases
Oncology
2017
24
47
Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma
Oncology
2020
24
48
Easy surveillance of muscle volume decline in chronic liver disease patients using finger‐circle (
yubi‐wakka
) test
Journal of Cachexia, Sarcopenia and Muscle
2019
23
49
Real‐world experience of 12‐week direct‐acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection
Journal of Gastroenterology and Hepatology (Australia)
2020
23
50
Huge Pancreatic Acinar Cell Carcinoma with High Levels of AFP and Fucosylated AFP (AFP-L3)
Internal Medicine
2012
22
site/software ©
exaly
; All materials licenced under
CC by-SA
.